Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Mu opioid receptor | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Echinococcus multilocularis | thyrotropin releasing hormone receptor | Mu opioid receptor | 398 aa | 371 aa | 27.0 % |
Schistosoma japonicum | ko:K04134 cholinergic receptor, invertebrate, putative | Mu opioid receptor | 398 aa | 334 aa | 24.9 % |
Onchocerca volvulus | Mu opioid receptor | 398 aa | 376 aa | 26.3 % | |
Onchocerca volvulus | Mu opioid receptor | 398 aa | 333 aa | 26.4 % | |
Echinococcus multilocularis | allatostatin A receptor | Mu opioid receptor | 398 aa | 341 aa | 29.3 % |
Onchocerca volvulus | Mu opioid receptor | 398 aa | 356 aa | 23.9 % | |
Schistosoma japonicum | Rhodopsin, putative | Mu opioid receptor | 398 aa | 328 aa | 23.2 % |
Echinococcus granulosus | allatostatin A receptor | Mu opioid receptor | 398 aa | 346 aa | 29.5 % |
Onchocerca volvulus | Mitochondrial inner membrane protein homolog | Mu opioid receptor | 398 aa | 334 aa | 23.1 % |
Schistosoma mansoni | neuropeptide F-like receptor | Mu opioid receptor | 398 aa | 335 aa | 20.6 % |
Schistosoma japonicum | ko:K04135 adrenergic receptor, alpha 1a, putative | Mu opioid receptor | 398 aa | 397 aa | 22.7 % |
Onchocerca volvulus | Programmed cell death protein 5 homolog | Mu opioid receptor | 398 aa | 323 aa | 24.1 % |
Echinococcus granulosus | thyrotropin releasing hormone receptor | Mu opioid receptor | 398 aa | 370 aa | 27.3 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | Conserved protein TB27.3 | 0.0747 | 0 | 0.5 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0747 | 0 | 0.5 |
Toxoplasma gondii | glyoxalase I, putative | 0.0747 | 0 | 0.5 |
Trypanosoma cruzi | lactoylglutathione lyase-like protein, putative | 0.0747 | 0 | 0.5 |
Schistosoma mansoni | gynecophoral canal protein | 0.0747 | 0 | 0.5 |
Onchocerca volvulus | Putative protein | 0.5091 | 1 | 1 |
Mycobacterium ulcerans | hypothetical protein | 0.0747 | 0 | 0.5 |
Mycobacterium tuberculosis | Conserved protein | 0.0747 | 0 | 0.5 |
Mycobacterium leprae | conserved hypothetical protein | 0.0747 | 0 | 0.5 |
Leishmania major | glyoxalase I,trypanothione-dependent glyoxalase I | 0.0747 | 0 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.0747 | 0 | 0.5 |
Mycobacterium ulcerans | glyoxalase GloA | 0.0747 | 0 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.0747 | 0 | 0.5 |
Trypanosoma cruzi | lactoylglutathione lyase-like protein, putative | 0.0747 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0747 | 0 | 0.5 |
Plasmodium falciparum | glyoxalase I | 0.0747 | 0 | 0.5 |
Plasmodium vivax | glyoxalase I, putative | 0.0747 | 0 | 0.5 |
Mycobacterium tuberculosis | Cadmium inducible protein CadI | 0.0747 | 0 | 0.5 |
Plasmodium vivax | glyoxalase I, putative | 0.0747 | 0 | 0.5 |
Schistosoma mansoni | 4-hydroxyphenylpyruvate dioxygenase | 0.0747 | 0 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.0747 | 0 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.0747 | 0 | 0.5 |
Toxoplasma gondii | glyoxalase family protein | 0.0747 | 0 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.0747 | 0 | 0.5 |
Plasmodium falciparum | glyoxalase I | 0.0747 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0747 | 0 | 0.5 |
Mycobacterium ulcerans | biphenyl-2,3-diol 1,2-dioxygenase | 0.0747 | 0 | 0.5 |
Loa Loa (eye worm) | 4-hydroxyphenylpyruvate dioxygenase | 0.5091 | 1 | 1 |
Mycobacterium tuberculosis | Conserved protein | 0.0747 | 0 | 0.5 |
Mycobacterium ulcerans | glyoxalase GloA | 0.0747 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Ki (binding) | > 10000 nM | Displacement of [3H]DAMGO from mu opioid receptor in rat brain homogenate after 1 hr by liquid scintillation counting | ChEMBL. | 22677527 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.